Apellis reported a net loss of $92.2 million for the first quarter of 2025 compared to a net loss of $66.4 million for the same period in 2024. Cash. As of March 31, 2025, Apellis had $358.4 million ...

Generated $166.8 million in 1Q 2025 revenues, including $149.9 million in U.S. net product salesSYFOVRE® (pegcetacoplan injection) injection demand grew 4% quarter-over-quarter, with U.S. net product ...

Tracy Vineis; Vice President, Communications; Apellis Pharmaceuticals Inc. Cedric Francois; President, Chief Executive Officer, Co-Founder, Director; Apellis Pharmac ...

The FDA has granted Orphan Drug designation to BA-102 for the treatment of Phelan-McDermid syndrome, a rare neurodevelopmental disorder.